Merck & Co., Inc. OCI, before Reclassifications, Net of Tax, Attributable to Parent
Merck & Co., Inc. (MRK) reported OCI, before Reclassifications, Net of Tax, Attributable to Parent of $42.00 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-03.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent · last filed 2023-11-03
- Merck & Co., Inc. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2023-09-30 was $42.00M.
- Merck & Co., Inc. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2023-06-30 was $11.00M, a 82.81% decline year-over-year.
- Merck & Co., Inc. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2023-03-31 was -$38.00M, a 146.91% decline year-over-year.
- Merck & Co., Inc. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2022-09-30 was -$261.00M.
- Merck & Co., Inc. oci, before reclassifications, net of tax, attributable to parent for fiscal 2015 was $579.00M.
- Merck & Co., Inc. oci, before reclassifications, net of tax, attributable to parent for fiscal 2014 was -$2.11B, a 192.42% decline from fiscal 2013.
- Merck & Co., Inc. oci, before reclassifications, net of tax, attributable to parent for fiscal 2013 was $2.28B.
| Period end | OCI, before Reclassifications, Net of Tax, Attributable to Parent 3 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 6 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 9 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2023-09-30 | $42.00M 10-Q · filed 2023-11-03 | $53.00M derived: sum of 2 quarters · filed 2023-11-03 | $15.00M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $11.00M 10-Q · filed 2023-08-07 | -$27.00M 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | -$38.00M 10-Q · filed 2023-05-05 | |||
| 2022-09-30 | -$261.00M 10-Q · filed 2023-11-03 | -$197.00M derived: sum of 2 quarters · filed 2023-11-03 | -$116.00M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $64.00M 10-Q · filed 2023-08-07 | $145.00M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $81.00M 10-Q · filed 2023-05-05 | |||
| 2021-09-30 | -$36.00M 10-Q · filed 2022-11-03 | $1.42B derived: sum of 2 quarters · filed 2022-11-03 | $1.25B 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $1.45B 10-Q · filed 2022-08-05 | $1.29B 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | -$162.00M 10-Q · filed 2022-05-05 | |||
| 2020-09-30 | -$66.00M 10-Q · filed 2021-11-05 | -$89.00M derived: sum of 2 quarters · filed 2021-11-05 | -$283.00M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | -$23.00M 10-Q · filed 2021-08-09 | -$218.00M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$195.00M 10-Q · filed 2021-05-05 | |||
| 2019-09-30 | $34.00M 10-Q · filed 2020-11-05 | $78.00M derived: sum of 2 quarters · filed 2020-11-05 | $299.00M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $44.00M 10-Q · filed 2020-08-05 | $265.00M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $221.00M 10-Q · filed 2020-05-06 | |||
| 2018-09-30 | -$105.00M 10-Q · filed 2019-11-05 | -$274.00M derived: sum of 2 quarters · filed 2019-11-05 | -$273.00M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | -$169.00M 10-Q · filed 2019-08-06 | -$168.00M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $4.00M 10-Q · filed 2019-05-08 | |||
| 2017-09-30 | $150.00M 10-Q · filed 2018-11-06 | $142.00M derived: sum of 2 quarters · filed 2018-11-06 | $365.00M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | -$8.00M 10-Q · filed 2018-08-07 | $215.00M 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $223.00M 10-Q · filed 2018-05-08 | |||
| 2016-09-30 | -$144.00M 10-Q · filed 2016-11-07 | $8.00M derived: sum of 2 quarters · filed 2016-11-07 | $54.00M 10-Q · filed 2016-11-07 | $574.00M derived: sum of 4 quarters · filed 2016-11-07 |
| 2016-06-30 | $152.00M 10-Q · filed 2016-08-08 | $198.00M 10-Q · filed 2016-08-08 | $718.00M derived: sum of 3 quarters · filed 2016-08-08 | $574.00M derived: sum of 4 quarters · filed 2016-11-07 |
| 2016-03-31 | $46.00M 10-Q · filed 2016-05-09 | $566.00M derived: sum of 2 quarters · filed 2016-05-09 | $422.00M derived: sum of 3 quarters · filed 2016-11-07 | $349.00M derived: sum of 4 quarters · filed 2016-11-07 |
| 2015-12-31 | $520.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $376.00M derived: sum of 2 quarters · filed 2016-11-07 | $303.00M derived: sum of 3 quarters · filed 2016-11-07 | $579.00M 10-K · filed 2016-02-26 |
| 2015-09-30 | -$144.00M 10-Q · filed 2016-11-07 | -$217.00M derived: sum of 2 quarters · filed 2016-11-07 | $59.00M 10-Q · filed 2016-11-07 | -$1.22B derived: sum of 4 quarters · filed 2016-11-07 |
| 2015-06-30 | -$73.00M 10-Q · filed 2016-08-08 | $203.00M 10-Q · filed 2016-08-08 | -$1.07B derived: sum of 3 quarters · filed 2016-08-08 | -$1.63B derived: sum of 4 quarters · filed 2016-08-08 |
| 2015-03-31 | $276.00M 10-Q · filed 2016-05-09 | -$998.00M derived: sum of 2 quarters · filed 2016-05-09 | -$1.55B derived: sum of 3 quarters · filed 2016-05-09 | |
| 2014-12-31 | -$1.27B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | -$1.83B derived: sum of 2 quarters · filed 2016-02-26 | -$2.11B 10-K · filed 2016-02-26 | |
| 2014-09-30 | -$556.00M 10-Q · filed 2015-11-05 | -$835.00M 10-Q · filed 2015-11-05 | ||
| 2013-12-31 | $2.28B 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |